CIRCLE-Seq: A highly sensitive in vitro screen for genome-wide CRISPR-cas9 nuclease off-targets

Tsai, Shengdar Q, Nguyen, Nhu T, Malagon-Lopez, Jose, Topkar, Ved V, Aryee, Martin J, Joung, J Keith·2017·Nature Methods
DOI 10.1038/nmeth.4278

Cited by (816)

Items 101–200 of 816

  1. CRISPR off-target detection with DISCOVER-seq
    Beeke Wienert, Stacia K. Wyman, Charles D. Yeh, Bruce R. Conklin, Jacob E. Corn · 2020 · Nature Protocols
  2. The Promise and the Hope of Gene Therapy
    E. Papanikolaou, A. Bosio · 2021 · Frontiers in Genome Editing
  3. Next‐Generation Genotoxicology: Using Modern Sequencing Technologies to Assess Somatic Mutagenesis and Cancer Risk
    Jesse J. Salk, Scott R. Kennedy · 2019 · Environmental and Molecular Mutagenesis
  4. CRISPR-Induced Deletion with SaCas9 Restores Dystrophin Expression in Dystrophic Models In Vitro and In Vivo
    Benjamin L. Duchêne, Khadija Cherif, Jean-Paul Iyombe-Engembe, Antoine Guyon, Joël Rousseau, Dominique L. Ouellet, Xavier Barbeau, Patrick Lagüe, Jacques P. Tremblay · 2018 · Molecular Therapy
  5. Defining genome-wide CRISPR–Cas genome-editing nuclease activity with GUIDE-seq
    Nikolay L. Malinin, GaHyun Lee, Cícera Regina Lazzarotto, Yichao Li, Zongli Zheng, Nathalie T. Nguyen, Matthew R. Liebers, Ved V. Topkar, Anthony John Iafrate, Long P. Le et al. · 2021 · Nature Protocols
  6. Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing
    Grace E. McAuley, Gloria Yiu, Patrick C. Chang, Gregory A. Newby, Beatriz Campo-Fernández, Sorel T. Fitz‐Gibbon, Wu Xiaomeng, Sung-Hae Lee Kang, Amber Garibay, Jeffrey Butler et al. · 2023 · Cell
  7. Systematic evaluation of CRISPR-Cas systems reveals design principles for genome editing in human cells
    Yuanming Wang, Kaiwen Ivy Liu, Norfala-Aliah Binte Sutrisnoh, Harini Srinivasan, Junyi Zhang, Jia Li, Fan Zhang, John Lalith Charles Richard, Heyun Xing, Raghuvaran Shanmugam et al. · 2018 · Genome biology
  8. Frequency and mechanisms of LINE-1 retrotransposon insertions at CRISPR/Cas9 sites
    Jianli Tao, Qi Wang, Carlos Mendez‐Dorantes, Kathleen H. Burns, Roberto Chiarle · 2022 · Nature Communications
  9. Revisiting Risk Governance of GM Plants: The Need to Consider New and Emerging Gene-Editing Techniques
    Sarah Zanon Agapito-Tenfen, Arinze Stanley Okoli, Michael J. Bernstein, Odd-Gunnar Wikmark, Anne Ingeborg Myhr · 2018 · Frontiers in Plant Science
  10. Integrated design, execution, and analysis of arrayed and pooled CRISPR genome-editing experiments
    Matthew C. Canver, Maximilian Haeussler, Daniel E. Bauer, Stuart H. Orkin, Neville E. Sanjana, Ophir Shalem, Guo‐Cheng Yuan, Feng Zhang, Jean‐Paul Concordet, Luca Pinello · 2018 · Nature Protocols
  11. Potent and uniform fetal hemoglobin induction via base editing
    Thiyagaraj Mayuranathan, Gregory A. Newby, Ruopeng Feng, Yu Yao, Kalin D. Mayberry, Cícera Regina Lazzarotto, Yichao Li, Rachel M. Levine, Nikitha Nimmagadda, Erin Dempsey et al. · 2023 · Nature Genetics
  12. Prediction of off-target specificity and cell-specific fitness of CRISPR-Cas System using attention boosted deep learning and network-based gene feature
    Qiao Liu, Di He, Lei Xie · 2019 · PLoS Computational Biology
  13. Beyond the promise: evaluating and mitigating off-target effects in CRISPR gene editing for safer therapeutics
    Lopes, Rui, Prasad, Megana K. · 2024 · Frontiers in Bioengineering and Biotechnology
  14. CRISPR GUARD protects off-target sites from Cas9 nuclease activity using short guide RNAs
    Matthew A. Coelho, Etienne D. Braekeleer, Mike A. Firth, Michał Biśta, Sebastian Łukasiak, Maria Emanuela Cuomo, Ben Taylor · 2020 · Nature Communications
  15. Genome-wide CRISPR off-target prediction and optimization using RNA-DNA interaction fingerprints
    Qinchang Chen, Guohui Chuai, Haihang Zhang, Jin Tang, Liwen Duan, Huan Guan, Wenhui Li, Wannian Li, Jiaying Wen, Erwei Zuo et al. · 2023 · Nature Communications
  16. The clinical potential of gene editing as a tool to engineer cell‐based therapeutics
    Candice Ashmore‐Harris, Gilbert O. Fruhwirth · 2020 · Clinical and Translational Medicine
  17. In vivo HSC prime editing rescues Sickle Cell Disease in a mouse model
    Chang Long Li, Aphrodite Georgakopoulou, Gregory A. Newby, Peter J. Chen, Kelcee A. Everette, Kiriaki Paschoudi, Efthymia Vlachaki, Sucheol Gil, Anna Kate Anderson, Theodore Koob et al. · 2023 · Blood
  18. Off-Target Analysis in Gene Editing and Applications for Clinical Translation of CRISPR/Cas9 in HIV-1 Therapy
    A. Atkins, Cheng-Han Chung, A. Allen, W. Dampier, Theodore E. Gurrola, I. K. Sariyer, M. Nonnemacher, B. Wigdahl · 2021 · Frontiers in Genome Editing
  19. CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration
    Erin R. Burnight, Joseph C. Giacalone, Jessica A. Cooke, Jessica R. Thompson, Laura R. Bohrer, Kathleen R. Chirco, Arlene V. Drack, John H. Fingert, Kristan S. Worthington, Luke A. Wiley et al. · 2018 · Progress in Retinal and Eye Research
  20. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy
    Adrian Pickar‐Oliver, Veronica Gough, Joel D. Bohning, Siyan Liu, Jacqueline N. Robinson-Hamm, Heather Daniels, William H. Majoros, Garth W. Devlin, Aravind Asokan, Charles A. Gersbach · 2021 · Molecular Therapy
  21. Modeling CRISPR-Cas13d on-target and off-target effects using machine learning approaches
    Xiaolong Cheng, Zexu Li, Ruocheng Shan, Zihan Li, Shengnan Wang, Wenchang Zhao, Han Zhang, Lumen Chao, Jian Peng, Fei Teng et al. · 2023 · Nature Communications
  22. Class 2 CRISPR–Cas RNA-guided endonucleases: Swiss Army knives of genome editing
    Stefano Stella, Pablo Alcón, Guillermo Montoya · 2017 · Nature Structural & Molecular Biology
  23. Gold Nanomaterials‐Implemented CRISPR‐Cas Systems for Biosensing
    Ruijie Fu, Yunlei Xianyu · 2023 · Small
  24. Prediction-based highly sensitive CRISPR off-target validation using target-specific DNA enrichment
    Seung-Hun Kang, Wi-jae Lee, Ju-Hyun An, Jong‐Hee Lee, Young-Hyun Kim, Hanseop Kim, Yeounsun Oh, Young‐Ho Park, Yeung Bae Jin, Bong‐Hyun Jun et al. · 2020 · Nature Communications
  25. CRISPRitz: rapid, high-throughput and variant-aware in silico off-target site identification for CRISPR genome editing
    Samuele Cancellieri, Matthew C. Canver, Nicola Bombieri, Rosalba Giugno, Luca Pinello · 2019 · Bioinformatics
  26. Increasing CRISPR Efficiency and Measuring Its Specificity in HSPCs Using a Clinically Relevant System
    Jenny Shapiro, Ortal Iancu, Ashley M. Jacobi, Matthew McNeill, Rolf Turk, Garrett R. Rettig, Ido Amit, Adi Tovin, Zohar Yakhini, Mark A. Behlke et al. · 2020 · Molecular Therapy — Methods & Clinical Development
  27. CRISPR Variants for Gene Editing in Plants: Biosafety Risks and Future Directions
    Ali Movahedi, Soheila Aghaei Dargiri, Hongyan Li, Qiang Zhuge, Weibo Sun · 2023 · International Journal of Molecular Sciences
  28. CRISPR/Cas9 gene-editing strategies in cardiovascular cells
    Eva Vermersch, Charlène Jouve, Jean‐Sébastien Hulot · 2019 · Cardiovascular Research
  29. Gene Editing of HIV-1 Co-receptors to Prevent and/or Cure Virus Infection
    Alexander G. Allen, Cheng-Han Chung, Andrew Atkins, Will Dampier, Kamel Khalili, Michael R. Nonnemacher, Brian L. Wigdahl · 2018 · Frontiers in Microbiology
  30. Gene editing and its applications in biomedicine
    Guanglei Li, Xiangyang Li, Songkuan Zhuang, Liren Wang, Yifan Zhu, Yangcan Chen, Wen Ce Sun, Zeguang Wu, Zhuo Long Zhou, Jia Chen et al. · 2022 · Science China Life Sciences
  31. CRISPR/Cas- and Topical RNAi-Based Technologies for Crop Management and Improvement: Reviewing the Risk Assessment and Challenges Towards a More Sustainable Agriculture
    Fabiano T. P. K. Távora, Francisco de Assis dos Santos Diniz, Camila M. Rêgo-Machado, Natália Chagas Freitas, Fabrício Barbosa Monteiro Arraes, Eduardo Chumbinho de Andrade, Leila Lourenço Furtado, Karen Ofuji Osiro, Natália Lima de Sousa, Thiago Bergamo Cardoso et al. · 2022 · Frontiers in Bioengineering and Biotechnology
  32. Could artificial intelligence revolutionize the development of nanovectors for gene therapy and mRNA vaccines?
    Akbar Hasanzadeh, Michael Richard Hamblin, Jafar Kiani, Hamid Noori, Joseph Michael Hardie, Mahdi Karimi, Hadi Shafiee · 2022 · Nano Today
  33. Non-viral chimeric antigen receptor (CAR) T cells going viral
    H. Balke-Want, V. Keerthi, Amaia Cadinanos-Garai, C. Fowler, N. Gkitsas, Annie K. Brown, Ramya H. Tunuguntla, Mohamed Abouelenein, Steven A. Feldman · 2023 · Immuno-Oncology Technology
  34. Guidelines for Optimized Gene Knockout Using CRISPR/Cas9
    Claude Van Campenhout, Pauline Cabochette, Anne-Clémence Veillard, Miklós Laczik, Agnieszka Zelisko-Schmidt, Céline Sabatel, Maxime Dhainaut, Benoît Vanhollebeke, Cyril Gueydan, Véronique Kruys · 2019 · BioTechniques
  35. New considerations for hiPSC-based models of neuropsychiatric disorders
    Gabriel E. Hoffman, Nadine Schrode, Erin K. Flaherty, Kristen Brennand · 2018 · Molecular Psychiatry
  36. BCL11A enhancer–edited hematopoietic stem cells persist in rhesus monkeys without toxicity
    Selami Demirci, Jing Zeng, Yuxuan Wu, Naoya Uchida, Anne H. Shen, Danilo Pellin, Jackson Gamer, Morgan Yapundich, Claire M. Drysdale, Jasmine Bonanno et al. · 2020 · Journal of Clinical Investigation
  37. Evolving AAV-delivered therapeutics towards ultimate cures
    Xijing He, Brian Anugerah Urip, Zhenjie Zhang, Chun Christopher Ngan, Bo Feng · 2021 · Journal of Molecular Medicine
  38. Genomic and Transcriptomic Analyses of Prime Editing Guide RNA–Independent Off-Target Effects by Prime Editors
    Runze Gao, Zhi-Can Fu, Xiangyang Li, Ying Wang, Jia Wei, Guangye Li, Lijie Wang, Jing Wu, Xingxu Huang, Li Chun Yang et al. · 2022 · The CRISPR Journal
  39. Systematic optimization of prime editing for the efficient functional correction of CFTR F508del in human airway epithelial cells
    Alexander A. Sousa, Colin F. Hemez, Lei Lei, Soumba Traore, Katarina Kulhánková, Gregory A. Newby, Jordan L. Doman, Keyede Oye, Smriti Pandey, Philip H. Karp et al. · 2024 · Nature Biomedical Engineering
  40. MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC
    Elena Fiorini, Antonia Malinova, Daniel Schreyer, Davide Pasini, Michele Bevere, Giorgia Alessio, Diego Rosa, Sabrina L. D’Agosto, Luca Azzolin, Salvatore Milite et al. · 2025 · Nature
  41. Unified energetics analysis unravels SpCas9 cleavage activity for optimal gRNA design
    Dong Zhang, Travis Hurst, Dongsheng Duan, Shi‐Jie Chen · 2019 · Proceedings of the National Academy of Sciences
  42. Advances in detecting and reducing off-target effects generated by CRISPR-mediated genome editing
    Jinjing Li, Shunyan Hong, Wan‐Jin Chen, Erwei Zuo, Hui Yang · 2019 · Journal of genetics and genomics/Journal of Genetics and Genomics
  43. An artificial triazole backbone linkage provides a split-and-click strategy to bioactive chemically modified CRISPR sgRNA
    Lapatrada Taemaitree, Arun Shivalingam, Afaf Helmy El-Sagheer, Tom P Brown · 2019 · Nature Communications
  44. Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment
    Francesco Marchetti, Renato Cardoso, Connie L. Chen, George R. Douglas, Joanne M. Elloway, Patricia A. Escobar, Tod A. Harper, Robert H. Heflich, Darren Kidd, Anthony M. Lynch et al. · 2023 · Mutation Research/Reviews in Mutation Research
  45. Amplification-free long-read sequencing reveals unforeseen CRISPR-Cas9 off-target activity
    Ida Höijer, Josefin Johansson, Sanna Gudmundsson, Chen-Shan Chin, Ignas Bunikis, Susana Häggqvist, Anastasia Emmanouilidou, Maria Wilbe, Marcel den Hoed, Marie-Louise Bondeson et al. · 2020 · Genome biology
  46. Human germline genome editing
    Rebecca A. Lea, Kathy K. Niakan · 2019 · Nature Cell Biology
  47. Gene Editing and Genotoxicity: Targeting the Off-Targets
    Georges Blattner, Alessia Cavazza, Adrian James Thrasher, Giandomenico Turchiano · 2020 · Frontiers in Genome Editing
  48. ON-Target Adverse Events of CRISPR-Cas9 Nuclease: More Chaotic than Expected
    Julian Boutin, David Cappellen, Juliette Rosier, Samuel Amintas, Sandrine Dabernat, Aurélie Bedel, François Moreau‐Gaudry · 2022 · The CRISPR Journal
  49. CRISPR nuclease off-target activity and mitigation strategies
    Beeke Wienert, M. Kyle Cromer · 2022 · Frontiers in Genome Editing
  50. Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
    Emmanuel Donnadieu, Maik Luu, Miriam Alb, Brigitte Anliker, Silvia Arcangeli, Chiara Bonini, Biagio De Angelis, Rashmi Choudhary, David Espie, Anne H. M. Galy et al. · 2022 · Journal for ImmunoTherapy of Cancer
  51. On- and off-target effects of paired CRISPR-Cas nickase in primary human cells
    Julia Klermund, Manuel Rhiel, Thomas Köcher, Kay Ole Chmielewski, Johannes Bischof, Geoffroy Andrieux, Melina el Gaz, Stefan Hainzl, Melanie Boerries, Tatjana I. Cornu et al. · 2024 · Molecular Therapy
  52. CRISPR system: Discovery, development and off-target detection
    Shengmiao Chen, Yufeng Yao, Yanchun Zhang, Gaofeng Fan · 2020 · Cellular Signalling
  53. Inhibition of HBV Expression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9
    Li, Hao, Sheng, Chunyu, Liu, Hongbo, Wang, Shan, Zhao, Jiangyun, Yang, Lang, Jia, Leili, Li, Peng, Wang, Ligui, Xie, Jing et al. · 2018 · Frontiers in Immunology
  54. Visual function restoration in a mouse model of Leber congenital amaurosis via therapeutic base editing
    Dong Hyun Jo, Hyeon‐Ki Jang, Chang Sik Cho, Jun Hee Han, Gahee Ryu, Youngri Jung, Sangsu Bae, Jeong Hun Kim · 2022 · Molecular Therapy — Nucleic Acids
  55. Quantification of Cas9 binding and cleavage across diverse guide sequences maps landscapes of target engagement
    Evan A. Boyle, Winston R. Becker, Hua Bai, Janice S. Chen, Jennifer A. Doudna, William James Greenleaf · 2021 · Science Advances
  56. Next-generation cell therapies: the emerging role of CAR-NK cells
    Rafet Başar, May Daher, Katayoun Rezvani · 2020 · Hematology
  57. The rapidly advancing Class 2 CRISPR‐Cas technologies: A customizable toolbox for molecular manipulations
    Jingyi Wang, Chenzi Zhang, Bo Feng · 2020 · Journal of Cellular and Molecular Medicine
  58. High-fidelity SaCas9 identified by directional screening in human cells
    Haihua Xie, Xianglian Ge, Fayu Yang, Bang Wang, Shuang Li, Jinzhi Duan, Xiujuan Lv, Congsheng Cheng, Zongming Song, Changbao Liu et al. · 2020 · PLoS Biology
  59. Suppression of unwanted CRISPR-Cas9 editing by co-administration of catalytically inactivating truncated guide RNAs
    John C. Rose, Nicholas A. Popp, Chris D. Richardson, Jason J. Stephany, Julie Mathieu, Cindy T. Wei, Jacob E. Corn, Dustin J. Maly, Douglas M. Fowler · 2020 · Nature Communications
  60. Tracking-seq reveals the heterogeneity of off-target effects in CRISPR–Cas9-mediated genome editing
    Ming Zhu, Runda Xu, Junsong Yuan, Jiacheng Wang, Xiaoyu Ren, Tingting Cong, Yaxian You, Anji Ju, Longchen Xu, Huimin Wang et al. · 2024 · Nature Biotechnology
  61. Engineered natural killer cells for cancer therapy
    Alexander Biederstädt, Katayoun Rezvani · 2025 · Cancer Cell
  62. CRISPR-Based Tools in Immunity
    Dimitre R. Simeonov, Alexander Marson · 2019 · Annual Review of Immunology
  63. ITR-Seq, a next-generation sequencing assay, identifies genome-wide DNA editing sites in vivo following adeno-associated viral vector-mediated genome editing
    Camilo Ayala Breton, Peter Clark, Lili Wang, Jenny A. Greig, James M. Wilson · 2020 · BMC Genomics
  64. CRISPR technologies for the treatment of Duchenne muscular dystrophy
    Eunyoung Choi, Taeyoung Koo · 2021 · Molecular Therapy
  65. Protein Inhibitors of CRISPR-Cas9
    Joseph Bondy‐Denomy · 2017 · ACS Chemical Biology
  66. Molecular mechanisms, off‐target activities, and clinical potentials of genome editing systems
    Nannan Zheng, Liyang Li, Xiangdong Wang · 2020 · Clinical and Translational Medicine
  67. CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination
    Jonathan Herskovitz, Mahmudul Hasan, Milankumar Patel, Wilson R. Blomberg, Jacob D. Cohen, Jatin Machhi, Daniel Stein, Evan A. Schroder, JoEllyn McMillan, Channabasavaiah B. Gurumurthy et al. · 2021 · EBioMedicine
  68. Systematic decomposition of sequence determinants governing CRISPR/Cas9 specificity
    Rongjie Fu, Wei He, Jinzhuang Dou, Oscar David Villarreal, Ella Bedford, Helen H. Wang, Connie Hou, Liang Zhang, Yalong Wang, Dacheng Ma et al. · 2022 · Nature Communications
  69. Integrating machine learning and genome editing for crop improvement
    Long Chen, Guanqing Liu, Tao Zhang · 2024 · aBIOTECH
  70. CRISPR-Cas9 targeting of MMP13 in human chondrocytes leads to significantly reduced levels of the metalloproteinase and enhanced type II collagen accumulation
    Christine Ilona Seidl, Tudor A. Fulga, Christopher L. Murphy · 2018 · Osteoarthritis and Cartilage
  71. AmpUMI: design and analysis of unique molecular identifiers for deep amplicon sequencing
    Kendell Clement, Rick Farouni, Daniel E. Bauer, Luca Pinello · 2018 · Bioinformatics
  72. Computational Tools and Resources Supporting CRISPR-Cas Experiments
    Paweł Śledziński, Mateusz Nowaczyk, Marta Olejniczak · 2020 · Cells
  73. Genome-wide detection of CRISPR editing in vivo using GUIDE-tag
    Liang, Shun-Qing, Liu, Pengpeng, Smith, Jordan L., Mintzer, Esther, Maitland, Stacy, Dong, Xiaolong, Yang, Qiyuan, Lee, Jonathan, Haynes, Cole M., Zhu, Lihua Julie et al. · 2022 · Nature Communications
  74. In vivo base editing extends lifespan of a humanized mouse model of prion disease
    Meirui An, Jessie R. Davis, Jonathan Ma Levy, Fiona E. Serack, John W. Harvey, Pamela P. Brauer, Catherine P. Pirtle, Kiara N. Berríos, Gregory A. Newby, Wei-Hsi Yeh et al. · 2025 · Nature Medicine
  75. Transitioning from wet lab to artificial intelligence: a systematic review of AI predictors in CRISPR
    Ahtisham Fazeel Abbasi, Muhammad Nabeel Asim, Andreas Dengel · 2025 · Journal of Translational Medicine
  76. Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease
    Paula Germino-Watnick, Malikiya Hinds, Anh Le, Rebecca Chu, Xiong Liu, Naoya Uchida · 2022 · Cells
  77. Recognition of CRISPR/Cas9 off‐target sites through ensemble learning of uneven mismatch distributions
    Hui Peng, Yi Zheng, Zhixun Zhao, Tao Liu, Jinyan Li · 2018 · Bioinform.
  78. CRISPR-Cas9 treatment partially restores amyloid-β 42/40 in human fibroblasts with the Alzheimer’s disease PSEN1 M146L mutation
    Evangelos Konstantinidis, Agnieszka Molisak, Florian Perrin, Linn Streubel-Gallasch, Sarah Fayad, Daniel Y. Kim, Karl Petri, Martin J. Aryee, Ximena Aguilar, Bence György et al. · 2022 · Molecular Therapy — Nucleic Acids
  79. Improving the sensitivity of in vivo CRISPR off-target detection with DISCOVER-Seq+
    Roger S. Zou, Yang Liu, Oscar E. Reyes Gaido, Maximilian F. Konig, Brian J. Mog, Leo L. Shen, Franklin J. Avilés-Vázquez, Alberto Marín-González, Taekjip Ha · 2023 · Nature Methods
  80. Anticipating and Identifying Collateral Damage in Genome Editing
    Gaétan Burgio, Lydia Teboul · 2020 · Trends in Genetics
  81. In vivo prime editing rescues alternating hemiplegia of childhood in mice
    Alexander A. Sousa, Markus Terrey, Holt A. Sakai, Christine Q. Simmons, Elena Arystarkhova, Natalia S. Morsci, Laura C. Anderson, Jun Xie, Fabian Suri‐Payer, Linda C. Laux et al. · 2025 · Cell
  82. Systematic identification of plausible pathways to potential harm via problem formulation for investigational releases of a population suppression gene drive to control the human malaria vector Anopheles gambiae in West Africa
    John B. Connolly, John D Mumford, Silke Fuchs, Geoff Turner, Camilla Beech, Ace R. North, Austin Burt · 2021 · Malaria Journal
  83. Precise detection of CRISPR-Cas9 editing in hair cells in the treatment of autosomal dominant hearing loss
    Chong Cui, Daqi Wang, Bowei Huang, Fang Wang, Yuxin Chen, Jun Lv, Luping Zhang, Lei Han, Dong Liu, Zheng‐Yi Chen et al. · 2022 · Molecular Therapy — Nucleic Acids
  84. Clinical applications of CRISPR‐based genome editing and diagnostics
    Dana Vera Foss, Megan L. Hochstrasser, Ross C. Wilson · 2019 · Transfusion
  85. Evaluation of CRISPR gene-editing tools in zebrafish
    José M. Uribe‐Salazar, Gulhan Kaya, Aadithya Sekar, KaeChandra Weyenberg, Cole Ingamells, Megan Y. Dennis · 2022 · BMC Genomics
  86. Gene Editing of Hematopoietic Stem Cells: Hopes and Hurdles Toward Clinical Translation
    Samuele Ferrari, Valentina Vavassori, Daniele Canarutto, Aurélien Jacob, Maria Carmina Castiello, Attya Omer, Pietro Genovese · 2021 · Frontiers in Genome Editing
  87. TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges
    E. Golikova, A. Alshevskaya, S. Alrhmoun, N. Sivitskaya, Sergey V. Sennikov · 2024 · Journal of Translational Medicine
  88. Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T cells and hematopoietic stem and progenitor cells using base editing
    Friederike Knipping, Gregory A. Newby, Cindy R. Eide, Amber N. McElroy, Sarah C. Nielsen, Kyle D. Smith, Yongxing Fang, Tatjana I. Cornu, Caroline Costa, Alejandra Gutiérrez-Guerrero et al. · 2021 · Molecular Therapy
  89. Maybe you can turn me on: CRISPRa-based strategies for therapeutic applications
    Elvir Bećirović · 2022 · Cellular and Molecular Life Sciences
  90. Genome editing in the mouse brain with minimally immunogenic Cas9 RNPs
    Elizabeth C. Stahl, Jennifer K. Sabo, Min Hyung Kang, Ryan Allen, Elizabeth Applegate, Shineui Kim, Yoonjin Kwon, Anmol Seth, Nicholas Lemus, Viviana Salinas-Rios et al. · 2023 · Molecular Therapy
  91. Benchmarking deep learning methods for predicting CRISPR/Cas9 sgRNA on- and off-target activities
    Zhang, Guishan, Luo, Ye, Dai, Xianhua, Dai, Zhiming · 2023 · Briefings in Bioinformatics
  92. Use of CRISPR/Cas9 gene-editing tools for developing models in drug discovery
    Gulzar Ahmad, Mansoor M. Amiji · 2018 · Drug Discovery Today
  93. CRISPR/Cas9 System: A Bacterial Tailor for Genomic Engineering
    Bilal Ahmad Lone, Shibendra Kumar Lal Karna, Faiz Ahmad, Nerina Shahi, Yuba Raj Pokharel · 2018 · Genetics Research International
  94. Effective use of sequence information to predict CRISPR-Cas9 off-target
    Zhong-Rui Zhang, Zhenran Jiang · 2022 · Computational and Structural Biotechnology Journal
  95. Prime editing: therapeutic advances and mechanistic insights
    Joss B. Murray, Patrick T. Harrison, Janine Scholefield · 2024 · Gene Therapy
  96. Combining Rapid Data Independent Acquisition and CRISPR Gene Deletion for Studying Potential Protein Functions: A Case of HMGN1
    Martin Mehnert, Wenxue Li, Chongde Wu, Barbora Šalovská, Yansheng Liu · 2019 · PROTEOMICS
  97. Technologies and Computational Analysis Strategies for CRISPR Applications
    Kendell Clement, Jonathan Y. Hsu, Matthew C. Canver, J. Keith Joung, Luca Pinello · 2020 · Molecular Cell
  98. eccDNAdb: a database of extrachromosomal circular DNA profiles in human cancers
    Li Peng, Nan Zhou, Chaoyang Zhang, Guan‐Cheng Li, Xiaoqing Yuan · 2022 · Oncogene
  99. Analysis of off-target effects in CRISPR-based gene drives in the human malaria mosquito
    William T. Garrood, Nace Kranjc, Karl Petri, Daniel Y. Kim, Jimmy A. Guo, Andrew Hammond, Ioanna Morianou, Vikram Pattanayak, J. Keith Joung, Andrea Crisanti et al. · 2021 · Proceedings of the National Academy of Sciences
  100. CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool
    Sadegh Shojaei Baghini, Zhanna R. Gardanova, Saeme Azizi Hassan Abadi, Burhan Abdullah Zaman, Ahmet İlhan, Navid Shomali, Ali Adili, Roozbeh Moghaddar, Amirhossein Fakhre Yaseri · 2022 · Cellular & Molecular Biology Letters